ALAMEDA, Calif., Feb. 22 /PRNewswire-FirstCall/ -- Xenogen Corporation , maker of advanced imaging systems including instruments, biological solutions and software designed to accelerate drug discovery and development, today announced that it will release 2005 fourth quarter and full-year financial results after the close of market on Thursday, March 2, 2006. Xenogen's management will host a conference call at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
What:
Xenogen will release 2005 fourth quarter and full-year results, followed by a teleconference.
When:
Teleconference begins on Thursday, March 2nd at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Who:
David Carter, Chief Executive Officer and Chairman; Dr. Pamela Contag, President; William Albright, Chief Financial Officer.
How:
Dial 800-946-0706 (domestic) or 719-457-2638 (international) to listen to the call. A live webcast also will be made available at www.xenogen.com.
A phone replay will be available for 48 hours following the completion of the call by dialing 888-203-1112 (domestic) or 719-457-0820 (international), and entering in reservation code 5244395. The webcast will be archived and available on the Xenogen website for 14 days.
About Xenogen Corporation
Xenogen Corporation is a leading biotechnology company offering an integrated suite of biophotonic real-time in vivo imaging and genetic modification technologies that can help expedite drug discovery and development, and significantly reduce the cost and time to market for new therapies. Xenogen's VivoVision(TM) Systems non-invasively illuminate and monitor biological processes within living mammals, at the molecular level, in real time. The technology provides higher quality in vivo data earlier in the drug discovery and development process. VivoVision(TM) Solutions improve discovery and pre-clinical research in multiple therapeutic areas. VivoVision(TM) Biosciences represents more than 15 years of experience in the creation and characterization of animal models, including genetic modifications, comprehensive phenotyping, compound profiling and custom design and production of light producing cells, microorganisms and animals.
More information is available at www.xenogen.com.
NOTE: Xenogen(R), Living Image(R), VivoVision(TM) and IVIS(R) are trademarks of Xenogen Corporation.
Xenogen CorporationCONTACT: William A. Albright, Chief Financial Officer of XenogenCorporation, +1-510-291-6104; or investors, Jordan Goldstein of FinancialDynamics, +1-415-439-4500, for Xenogen Corporation; or media, Kelly O'Brienof Manning Selvage & Lee, +1-415-364-3840, for Xenogen Corporation
Web site: http://www.xenogen.com/
